The Oncologist, Vol. 11, No. 10, 1047-1057, November 2006; doi:10.1634/theoncologist.11-10-1047
© 2006 AlphaMed Press
Lapatinib: Current Status and Future Directions in Breast Cancer
Beverly Moy,
Paul E. Goss
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Key Words. Lapatinib • GW572016 • Dual tyrosine kinase inhibitor • Breast cancer • EGFR • ErbB-1 • ErbB-2 • HER-2
Correspondence:
Paul E. Goss, M.D., Ph.D., Massachusetts General Hospital Cancer Center, Gillette Center for Womens Cancers, 55 Fruit Street, Lawrence House, LRH 302, Boston, Massachusetts 02114, USA. Telephone: 617-724-3118; Fax: 617-643-0589; e-mail: pgoss{at}partners.org
Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors. Pre-clinical in vitro and in vivo models indicate that lapatinib is active as monotherapy, synergistically in combination with trastuzumab, and in trastuzumab-resistant cell lines. Early clinical trials also provide evidence in patients that lapatinib is active against breast cancer. This paper reviews results of phase II and III clinical trials of lapatinib in metastatic breast cancer, evidence for its potential in patients with brain metastases, and current clinical trials as adjuvant treatment in early-stage disease. Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes is allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.
This article has been cited by other articles:

|
 |

|
 |
 
B. K. Dahal, T. Cornitescu, A. Tretyn, S. S. Pullamsetti, D. Kosanovic, R. Dumitrascu, H. A. Ghofrani, N. Weissmann, R. Voswinckel, G.-A. Banat, et al.
Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
January 15, 2010;
181(2):
158 - 167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Purcell, J. Davis, M. Reddy, S. Martin, K. Samayoa, H. Vo, K. Thomsen, P. Bean, W. L. Kuo, S. Ziyad, et al.
Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer
Clin. Cancer Res.,
January 15, 2010;
16(2):
566 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Leow, J. Chesebrough, K. T. Coffman, C. A. Fazenbaker, J. Gooya, D. Weng, S. Coats, D. Jackson, B. Jallal, and Y. Chang
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2131 - 2141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xie, D. W. Wolff, T. Wei, B. Wang, C. Deng, J. K. Kirui, H. Jiang, J. Qin, P. W. Abel, and Y. Tu
Breast Cancer Migration and Invasion Depend on Proteasome Degradation of Regulator of G-Protein Signaling 4
Cancer Res.,
July 15, 2009;
69(14):
5743 - 5751.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Ann. Onc.,
June 1, 2009;
20(6):
1026 - 1031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc.,
June 1, 2009;
84(6):
533 - 545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. B. Contractor and E. O. Aboagye
Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
97S - 105S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist,
April 1, 2009;
14(4):
320 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Polli, K. L. Olson, J. P. Chism, L. St. John-Williams, R. L. Yeager, S. M. Woodard, V. Otto, S. Castellino, and V. E. Demby
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
Drug Metab. Dispos.,
February 1, 2009;
37(2):
439 - 442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Molina, S. H. Kaufmann, J. M. Reid, S. D. Rubin, M. Galvez-Peralta, R. Friedman, K. S. Flatten, K. M. Koch, T. M. Gilmer, R. J. Mullin, et al.
Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Clin. Cancer Res.,
December 1, 2008;
14(23):
7900 - 7908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Paul, J. A. Trovato, and J. Thompson
Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
Am. J. Health Syst. Pharm.,
September 15, 2008;
65(18):
1703 - 1710.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
J. Clin. Oncol.,
July 10, 2008;
26(20):
3317 - 3323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Polli, J. E. Humphreys, K. A. Harmon, S. Castellino, M. J. O'Mara, K. L. Olson, L. St. John-Williams, K. M. Koch, and C. J. Serabjit-Singh
The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions
Drug Metab. Dispos.,
April 1, 2008;
36(4):
695 - 701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Oncologist,
December 1, 2007;
12(12):
1443 - 1455.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Moy and P. E. Goss
Lapatinib-Associated Toxicity and Practical Management Recommendations
Oncologist,
July 1, 2007;
12(7):
756 - 765.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by AlphaMed Press.
|
|